Special Issue

Diagnosis and Treatment of Skin Diseases in Light of Molecular Medicine

Message from the Guest Editor

Dermatology is an ongoing field, with more and more precise reclassifications. This tremendous progress has a solid foundation: a greater understanding of molecular mechanisms. Nowadays, diagnostic methods have gained accuracy and enable rapid global interconnection between individuals within different continents. Targeting molecules in psoriasis, atopic dermatitis, and melanoma opens the door toward an immunological approach to the skin, an amazing immune organ. The escape mechanisms of sexually transmitted disease pathogens or detailed characterizations of herpetic viruses (e.g., Epstein-Barr as number four, CMV as number five) are topics of interest that move forward in this field. We look forward to receiving original papers and literature reviews that use molecular medicine and clinical experience.

Guest Editor

Dr. Olga Simionescu

Chief of the First Clinic of Dermatology, Department of Dermatology, "Carol Davila" University of Medicine and Pharmacy, Colentina Hospital, 020125 Bucharest, Romania

Deadline for manuscript submissions

closed (31 January 2024)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/167093

Biomedicines MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health. Boston. MA 02115. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).